Federal Contractor Profile
Biofactura INC
Federal contracting record: $67M obligated across 3 awards from 2 agencies, FY 2018–2025.
Company Profile
Parent UEI (Unique Entity Identifier)
C1ZWQAYK4J58
CAGE Code
339S7
Address
8435 PROGRESS DR STE Z, FREDERICK, MD, 217014981
First Federal Award
Apr 12, 2018
Most Recent Award
Sep 23, 2025
Federal Sales Analytics
Toggle between trend, agency drilldown, and treemap. Use the period selector to focus the time window.
Hover any bar for YoY change + award count. Current fiscal year shown at reduced opacity (partial year).
Top Federal Agencies
- $66M
Department of Health and Human Services
98.3% of total obligations
- $1.1M
Department of Defense
1.7% of total obligations
Top NAICS Activity
- $67M
541714
RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
2 awards
- $150K
325411
MEDICINAL AND BOTANICAL MANUFACTURING
1 awards
Recent Federal Awards
| Date | Agency | NAICS | Description | Amount |
|---|---|---|---|---|
| Sep 19, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT INCLUDES PRECLINICAL AND MANUFACTURING DEVELOPMENT ACTIVITIES INCLUDING CELL LINE DEVELOPMENT PROCESS DEVELOPMENT NON-CLINICAL EFFICACY STUDIES NON-CLINICAL SAFETY STUDIES MANUFACTURING ACTIVITIES CLINICAL ACTIVITIES AND ALL AS | $7.8M |
| Sep 20, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT INCLUDES PRECLINICAL AND MANUFACTURING DEVELOPMENT ACTIVITIES INCLUDING CELL LINE DEVELOPMENT PROCESS DEVELOPMENT NON-CLINICAL EFFICACY STUDIES NON-CLINICAL SAFETY STUDIES MANUFACTURING ACTIVITIES CLINICAL ACTIVITIES AND ALL AS | $16M |
| Jun 16, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT INCLUDES PRECLINICAL AND MANUFACTURING DEVELOPMENT ACTIVITIES INCLUDING CELL LINE DEVELOPMENT PROCESS DEVELOPMENT NON-CLINICAL EFFICACY STUDIES NON-CLINICAL SAFETY STUDIES MANUFACTURING ACTIVITIES CLINICAL ACTIVITIES AND ALL AS | $928K |
| Mar 7, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT INCLUDES PRECLINICAL AND MANUFACTURING DEVELOPMENT ACTIVITIES INCLUDING CELL LINE DEVELOPMENT PROCESS DEVELOPMENT NON-CLINICAL EFFICACY STUDIES NON-CLINICAL SAFETY STUDIES MANUFACTURING ACTIVITIES CLINICAL ACTIVITIES AND ALL AS | $1.7M |
| Jun 28, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT INCLUDES PRECLINICAL AND MANUFACTURING DEVELOPMENT ACTIVITIES INCLUDING CELL LINE DEVELOPMENT PROCESS DEVELOPMENT NON-CLINICAL EFFICACY STUDIES NON-CLINICAL SAFETY STUDIES MANUFACTURING ACTIVITIES CLINICAL ACTIVITIES AND ALL AS | $16M |
| May 23, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT INCLUDES PRECLINICAL AND MANUFACTURING DEVELOPMENT ACTIVITIES INCLUDING CELL LINE DEVELOPMENT PROCESS DEVELOPMENT NON-CLINICAL EFFICACY STUDIES NON-CLINICAL SAFETY STUDIES MANUFACTURING ACTIVITIES CLINICAL ACTIVITIES AND ALL AS | $748K |
| Feb 10, 2021 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT INCLUDES PRECLINICAL AND MANUFACTURING DEVELOPMENT ACTIVITIES INCLUDING CELL LINE DEVELOPMENT PROCESS DEVELOPMENT NON-CLINICAL EFFICACY STUDIES NON-CLINICAL SAFETY STUDIES MANUFACTURING ACTIVITIES CLINICAL ACTIVITIES AND ALL AS | $13M |
| Jun 11, 2020 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | 541714 | PHASE II SBIR FOR PROCESS DEVELOPMENT AND MANUFACTURE OF AN ANTIBODY-BASED THERAPY AGAINST MARBURGVIRUS. | $999K |
| Sep 20, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT INCLUDES PRECLINICAL AND MANUFACTURING DEVELOPMENT ACTIVITIES INCLUDING CELL LINE DEVELOPMENT PROCESS DEVELOPMENT NON-CLINICAL EFFICACY STUDIES NON-CLINICAL SAFETY STUDIES MANUFACTURING ACTIVITIES CLINICAL ACTIVITIES AND ALL AS | $9.5M |
| Apr 12, 2018 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | 325411 | CBD SBIR 17.2 PHASE I PROPOSAL #C171-005-0003, PROCESS DEVELOPMENT AND MANUFACTURE OF AN ANTIBODY-BASED THERAPY AGAINST MARBURGVIRUS | $150K |
Related Contractors
Other companies active in NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY).
Want to win work like Biofactura INC?
Their contracts will eventually end — and when they do, the government has to award that work again. Mindy tells you up to a year early, so you can be ready to compete for it.